Pomalyst patent expiration?

Pomalyst (pomalidomide) – Where it is on the patent life‑cycle

What does this mean for patients and physicians?

• No generic has yet been approved in the United States as of 2024. The first opportunity for a generic applicant to file an ANDA (Abbreviated New Drug Application) is after the expiration of the use‑patents (20 Dec 2025). That is the earliest date when a company could potentially launch a generic version of pomalidomide for multiple‑myeloma indications.

• Even after the use‑patents expire, the formulation and process patents (expiry 2032–2036) still protect the specific oral dosage forms that Celgene (now part of Bristol Myers Squibb) manufactures. A generic could be approved for the active ingredient but would still have to navigate the remaining patents—usually by creating a different formulation or by seeking a new filing that falls outside the scope of the existing patents.

• For the European Union, the earliest generic filings could be expected in 2027, once the EU patents on the use and formulation expire.

• Commercial impact: Pomalyst remains a branded drug under Bristol Myers Squibb. The company continues to hold market exclusivity for the approved indications, and its revenue stream from pomalidomide is expected to be stable for at least a few more years after 2025.

Practical take‑away for clinicians

• Keep an eye on the 2025 expiration. If your health system is planning drug budgeting for next year, you’ll likely see the first generic‑ready for submission after that date.

• Monitor EU generic entry. Many European patients already have access to cheaper, generic versions of pomalidomide after 2027; this may influence cross‑border prescribing and reimbursement discussions.

• Consider combination regimens. The patents for pomalidomide + dexamethasone and other combinations also expire 2025, so generics of these combos could follow shortly after.

Bottom line

• Pomalyst’s core “use” patents expire on 20 December 2025**.
• Formulation and process patents extend to 2032–2036.
• No generic is currently approved in the US; the first generic submissions are expected post‑2025.

If you need the most current status (e.g., if a new patent has been granted or if a generic has been approved since early 2025), let me know and I can pull the latest USPTO data for you.